Intensified Chemoradiotherapy for Rectal Cancer
Author Information
Author(s): Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R
Primary Institution: University Hospital, Rostock, Germany
Hypothesis
This study aimed to evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy intensified with irinotecan in patients with locally advanced rectal cancer.
Conclusion
Intensified neoadjuvant chemoradiotherapy with irinotecan can be safely administered and results in a high pathologic complete response rate.
Supporting Evidence
- 89% of patients undergoing surgery had R0 resection.
- 22% of patients achieved a pathologic complete response.
- Overall survival at 4 years was 66%.
Takeaway
Doctors gave special treatment to patients with rectal cancer to help them before surgery, and it worked really well for many of them.
Methodology
Patients received preoperative radiation and chemotherapy with 5-fluorouracil and irinotecan over a period of 6 weeks.
Potential Biases
Potential selection bias due to the non-randomized nature of the study.
Limitations
The study had a small sample size and was limited to a specific patient population.
Participant Demographics
The study included 37 patients, 27 males and 10 females, with a median age of 62 years.
Statistical Information
P-Value
0.013
Confidence Interval
Not reported
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website